Keyphrases
Tissue Inhibitor of metalloproteinase-1 (TIMP-1)
100%
Fulvestrant
100%
Resistant Breast Cancer
100%
HER3
100%
Breast Cancer Cell Lines
100%
Resistant Cells
72%
Cell Growth
36%
Phosphorylation
27%
HER Receptors
27%
MCF-7
27%
MCF-7 Cells
27%
Breast Cancer Cells
18%
Growth Arrest
9%
Targeted Treatment
9%
Resistance Mechanisms
9%
Inhibitory Effect
9%
Estrogen Receptor
9%
Knockdown
9%
HER4
9%
Metalloproteinases
9%
Conditioned Medium
9%
Selective Inhibitor
9%
Growth Inhibition
9%
Antiestrogen Resistance
9%
Antiestrogen
9%
Multiple Strategies
9%
Gefitinib
9%
EGFR Inhibitors
9%
Receptor Activation
9%
Human Epidermal Growth Factor Receptor
9%
Heregulin
9%
Cell Treatment
9%
Medicine and Dentistry
Fulvestrant
100%
Metalloprotease Inhibitor
100%
Breast Cancer Cell Line
100%
MCF-7
75%
Cell Growth
50%
Breast Cancer
25%
Cancer Cell
25%
Epidermal Growth Factor Receptor
25%
Antiestrogen
25%
Receptor
12%
Estrogen Receptor
12%
Gamma Urogastrone
12%
EGFR Inhibitors
12%
Gefitinib
12%
Growth Inhibition
12%
Neu Differentiation Factor
12%
Metalloproteinase
12%
Biochemistry, Genetics and Molecular Biology
Cancer Cell
100%
Metalloprotease Inhibitor
100%
Fulvestrant
100%
Cell Growth
50%
Epidermal Growth Factor Receptor
37%
Eicosanoid Receptor
12%
Estrogen Receptor
12%
Metalloproteinase
12%
Metalloendopeptidase
12%
Growth Inhibition
12%
Gefitinib
12%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Fulvestrant
100%
Metalloproteinase Inhibitor
100%
Epidermal Growth Factor Receptor
37%
Antiestrogen
25%
Receptor
12%
Growth Disorder
12%
Gamma Urogastrone
12%
Estrogen Receptor
12%
Gefitinib
12%
Ilomastat
12%
Neu Differentiation Factor
12%
Metalloproteinase
12%